Back to Newsroom

Covagen Secures CHF 42 Million in Series B Financing

ZURICH-SCHLIEREN, Switzerland, Dec. 9, 2013 – Covagen today announced that the company has secured CHF 42 million in a tranched Series B financing with an option to obtain an additional CHF 14 million that would increase the total amount of the financing round to CHF 56 million. This is one of the largest private financing rounds for a preclinical-stage biotech company in Europe.